So $mnkd pays Zacks SCR $10's of thousands a year to write " research reports ". Recent paid report is rehash of the June10 poster on P2 N=15 ped study that will eventually have 46 subjects, was started in 2015 and is yrs from completion.
@SEC_Enforcement watch $MNKD for possible #REAL_TIME stock pumper manipulation. @US_FDA#FDA Office of Prescription Drug Promotion watch $mnkd social media including facebook groups for false and misleading claims denying risks and dangers of Black Box afrezza. $SNY $LLY $NOVO
$mnkd replying to @TheHarryx1 your parents must be so proud of you! Disgusting #desperate person pushing a dangerous inhaled hormone that's not better than other therapies. You either work for the company, a stock promotion firm or are just a despictable human being.
$mnkd baggies excited - founder of Samson hair restoration, who founded Vdex and is mnkd shareholder, feels vdex is disrespected and wants wholesale priced afrezza as "full right" pharmaceutical distributer - because their 3 places in CA and 3 in NM "work". LOL
LOL Zacks SCR has received compensation from the issuer directly or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. $mnkd
$mnkd Wk of 6/7/19 Nrx 332 Rrx 337. The official FDA Afrezza Label is clear cut - "AFREZZA provided less HbA1c reduction than insulin aspart, and the difference was statistically significant. More subjects in the insulin aspart group achieved the HbA1c target of ≤7% "
@TheHarryx1 14 subjects. No comparison to other insulins. At best more anecdotes. Real world scripts of new 259 refills 365 for a drug approved in 2014 is the reality. When will they do the FDA mandated post approval studies ( phase 4 ) ordered 5 years ago? #bagholder#desperate#underwater
@TheHarryx1 $mnkd The desperate bagholding pumper is back pushing p.r. bs about a failed drug using a study mnkd paid Levin $39K that isn't scientific and had 14 subjects. Afrezza label approved by FDA: AFREZZA provided less HbA1c reduction than insulin aspart. Needs Spirometry
LOL N=14 non- scientific study. Where are head-to-head studies against other short acting insulins. Of course adding insulin will lower A1C. FDA states " in type 2 diabetes Afrezza is less effective than a short acting subcutaneous insulin comparator. $mnkd Paid >$39K for this
Folks whining about $mnkd leadership again. The real problem is Afrezza itself. Despite anecdotal stories, likely from bagholders or shills the drug is simply unwanted and doesn't match current therapies. There's a reason Alkermes, $LLY $PFE, Aradigm, $NVO gave up inhaled insulin
@SEC_Enforcement watch $MNKD for possible #REAL_TIME stock pumper manipulation. @US_FDA#FDA Office of Prescription Drug Promotion watch $mnkd social media for false and misleading claims denying risks and dangers of Black Box afrezza. Thank You.
Another week of lousy Afrezza scripts. Then again it is a black box Dangerous powdered hormone that's inhaled into lungs. Will $mnkd ever do the safety trials FDA ordered 5 years ago?